Agilon Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports corporate governance actions by agilon health, Inc., a Delaware corporation whose common stock trades on the New York Stock Exchange under the symbol AGL. The report date and earliest reported event are July 9, 2021; the director appointment became effective July 12, 2021, and the filing was signed on July 12, 2021.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Changes Versus the Prior Comparable Period
- The Board approved increasing its size to eleven directors, effective July 12, 2021.
- Karen McLoughlin was elected as a Class II director to fill the vacancy created by the increase in Board size.
- Ms. McLoughlin was also appointed to the Board’s audit committee.
- She will serve until the 2023 annual general meeting of stockholders, unless earlier removed under the company’s amended and restated certificate of incorporation.
Guidance, Outlook, Risks, and Unusual Items
- The filing provides no financial guidance or business outlook.
- Ms. McLoughlin previously served as Chief Financial Officer of Cognizant Technology Solutions from 2012 to 2020 and currently serves on Best Buy’s board, including its audit committee.
- The company cited her public-company executive, board, financial, and accounting experience as qualifications for service.
- The company stated that there were no related-party transactions reportable under Item 5.02 of Form 8-K and Item 404(a) of Regulation S-K.
- Ms. McLoughlin will receive compensation under the company’s previously disclosed non-officer director compensation programs.
- The filing includes a July 12, 2021 press release announcing the appointment as Exhibit 99.1.
Important Facts for Investors to Verify
- Confirm the effective date of the board expansion and Ms. McLoughlin’s appointment: July 12, 2021.
- Review the company’s previously disclosed non-officer director compensation program for the applicable compensation terms.
- Review Exhibit 99.1 for the company’s full announcement and any additional biographical information.
- Assess any subsequent changes to board composition or audit committee membership in later SEC filings.